Hologic (NASDAQ: HOLX) shares soared 5.35% in Monday's trading session following the release of its fourth-quarter fiscal 2025 results, which surpassed analyst expectations across multiple metrics. The women's health company demonstrated robust performance amid ongoing acquisition talks with Blackstone and TPG.

The medical technology firm reported adjusted earnings per share of $1.13, beating the consensus estimate of $1.10. Revenue for the quarter climbed 6.2% year-over-year to $1.05 billion, outpacing analyst projections of $1.03 billion. Hologic's adjusted net income of $254.7 million and adjusted EBITDA of $347 million also exceeded Wall Street forecasts.

Hologic's strong quarterly performance was driven by growth across its product divisions. The diagnostics segment saw higher core U.S. molecular diagnostics sales, offsetting lower COVID-19 assay sales and reduced sales in China. The breast health division benefited from strong interventional product sales and improved U.S. sales execution, while the surgical revenue increased by over 10%, fueled by strong demand for MyoSure and Fluent systems. As Hologic moves forward with its planned acquisition by Blackstone and TPG for up to $79 per share, the company has refrained from providing financial guidance for fiscal 2026.